✦ LIBER ✦

Crizotinib continues to produce high response rates in ALK+ non-small cell lung cancer

✍ Scribed by NEIL OSTERWEIL

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

ALK translocation and crizotinib in non-

✍ Giorgio Scagliotti; Rolf A. Stahel; Rafael Rosell; Nick Thatcher; Jean-Charles S 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 892 KB

Effect of crizotinib on overall survival

✍ Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; J 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 250 KB

Activity and safety of crizotinib in pat

✍ D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella- 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 310 KB

ALK Inhibition for Non-Small Cell Lung C

✍ David E. Gerber; John D. Minna 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 108 KB

PCN73 Economic Analysis of the Use of Cr

✍ J.G. Gay-Molina; R. Sánchez-Kobashi; E. Muciño-Ortega; C.I. Gutiérrez-Colín; R.M 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

Predicting response to paclitaxel/carbop

✍ Rafael Rosell; Enriqueta Felip 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 946 KB